ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,328 GBX | -1.82% |
|
-0.56% | +16.30% |
| 12:39pm | US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug | RE |
| 26/06 | European Equities Close Lower in Wednesday Trading | MT |
Presenter SpeechAndrew Barnett (Executives)A warm welcome, everybody, to this 2023 ASCO event ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
158.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.30% | 25TCr | |
| +55.17% | 81TCr | |
| +43.62% | 64TCr | |
| -7.05% | 35TCr | |
| +18.13% | 33TCr | |
| +8.76% | 30TCr | |
| +2.41% | 22TCr | |
| +12.47% | 22TCr | |
| +8.53% | 17TCr | |
| -3.68% | 16TCr |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Transcript : AstraZeneca PLC Presents at 2023 American Society of Clinical Oncology Annual Meeting, Jun-02-2023 through Jun-06-2023
